Health Beat #31

WATCH | Can South Africa’s HIV fight survive US funding blows?

Health economists warn of a surge in new infections and deaths if South Africans forgo their treatment. Could an expensive HIV jab be the answer?

03 July 2025 - 04:30 By Anna-Maria van Niekerk, Mia Malan, Jessica Pitchford, Yolanda Mdzeke, Thatego Mashabela and Justin Barlow
subscribe Just R20 for the first month. Support independent journalism by subscribing to our digital news package.
Subscribe now
USAID-funded programmes helped millions of people around the world fight HIV/Aids and TB. Stock photo.
LIFESAVER USAID-funded programmes helped millions of people around the world fight HIV/Aids and TB. Stock photo.
Image: 123RF.COM/PENCHAN PUMILA

South Africa’s HIV programme, once sustained by US support, is at risk. Without replacement funding, South Africa could see a 38% increase in Aids-related deaths by 2028 and up to 150,000 HIV infections.

With some frontline services collapsing and mobile clinics funded by US emergency fund Pepfar lying idle, it’s feared many of South Africa’s eight-million people living with HIV might forgo their treatment.

The average person with HIV in South Africa is aged 41, which means treatment access isn’t just about survival; it’s about protecting our workforce.

But there’s a promising breakthrough: the US Food and Drug Administration has approved the HIV prevention jab, lenacapavir, and it could be registered in South Africa by early 2026. 

Health minister Aaron Motsoaledi told Health Beat he’ll find the money to buy the jab if donors can’t help. But how much should we pay for it?

Find out:

This story was produced by the Bhekisisa Centre for Health Journalism. Sign up for the newsletter.


subscribe Just R20 for the first month. Support independent journalism by subscribing to our digital news package.
Subscribe now

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.